The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Will The Market Size Of The Peanut Allergy Treatment Market Evolve From 2026 To 2030?
The peanut allergy treatment market size has seen substantial expansion in recent years. Its valuation is expected to rise from $0.5 billion in 2025 to $0.55 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.8%. This historical expansion can be linked to several factors, including the increasing incidence of peanut allergies among children, the restricted efficacy of avoidance-based management strategies, a rise in the identification of food allergies, the considerable reliance on epinephrine for urgent interventions, and heightened understanding among medical professionals.
The peanut allergy treatment market size is projected to experience substantial growth over the next few years. It is anticipated to expand to $0.8 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.7%. This expansion during the forecast period is driven by factors such as advancements in immunotherapy technologies, increasing approvals of disease-modifying treatments, a rising demand for preventive allergy care, the broadening application of biologics targeting allergic pathways, and growing investment in food allergy research. Notable trends expected during this period include the increasing adoption of oral immunotherapy for peanut desensitization, the expanding use of epicutaneous immunotherapy patches, greater integration of biologic therapies in allergy treatment, the proliferation of pediatric-focused peanut allergy treatments, and a stronger emphasis on long-term allergy management solutions.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15888&type=smp
Which Growth Drivers Are Contributing To The Progress Of The Peanut Allergy Treatment Market?
The continued investment in research and development for allergy treatments is expected to drive the future expansion of the peanut allergy treatment market. Research and development (R&D) investment refers to the financial resources allocated by companies, organizations, or governments towards activities focused on innovation, product creation, and technological advancement. This allocation of funds for allergy treatment R&D is crucial for advancing peanut allergy therapies. Such investment promotes the creation of innovative immunotherapies and desensitization techniques, designed to minimize allergic reactions and improve the quality of life for those affected by peanut allergies. For example, in January 2024, the Victorian Government announced a strategic $12 million investment in Aravax, an Australia-based clinical-stage biotechnology company, specifically to significantly advance global peanut allergy treatment. This funding is part of a broader $66 million round aimed at developing Aravax’s innovative immunotherapy, PVX108. This initiative has successfully secured Phase 2 trial approvals from both the U.S. Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA), emphasizing its potential worldwide public health impact. Therefore, investment in research and development of allergy treatments is a key factor propelling the growth of the peanut allergy treatment market.
Which Segment Areas Are Covered In The Peanut Allergy Treatment Market Analysis?
The peanut allergy treatment market covered in this report is segmented –
1) By Drug Class: Antihistamines, Immunotherapies, Epinephrine, Other Drug Classes
2) By Route Of Administration: Injectable, Oral, Other Routes Of Administration
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels
Subsegments:
1) By Antihistamines: Oral Antihistamines, Topical Antihistamines
2) By Immunotherapies: Oral Immunotherapy (OIT), Sublingual Immunotherapy (SLIT), Epicutaneous Immunotherapy (EPIT)
3) By Epinephrine: Epinephrine Auto-Injectors, Epinephrine Inhalers
4) By Other Drug Classes: Leukotriene Receptor Antagonists, Monoclonal Antibodies, Corticosteroids
What Key Developments And Trends Are Impacting The Peanut Allergy Treatment Market?
Key companies in the peanut allergy treatment market are prioritizing the creation of biologic therapies, including anti-IgE monoclonal antibodies. These therapies aim to deliver more targeted and effective options for managing peanut allergies, with the objective of enhancing patient outcomes and their quality of life. Anti-IgE monoclonal antibodies function as therapeutic agents specifically designed to target and neutralize immunoglobulin E (IgE) antibodies within the body. For example, in February 2024, Novartis Pharmaceuticals Corporation, a Switzerland-based pharmaceutical company, obtained approval from the Food and Drug Administration (FDA) for Xolair (omalizumab). This medication is designed to diminish allergic reactions, including anaphylaxis, in patients aged 1 year and older who have IgE-mediated food allergies. The approval decision was founded on data from the NIH-sponsored Phase III OUtMATCH study, which demonstrated a notable improvement in food allergy tolerance among patients treated with Xolair, as opposed to those given a placebo.
Which Global Companies Are Actively Competing In The Peanut Allergy Treatment Market?
Major companies operating in the peanut allergy treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Viatris Inc., Regeneron Pharmaceuticals Inc., Hikma Pharmaceuticals plc, ALK-Abelló A/S, Amneal Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc, Stallergenes Greer plc, kaleo Inc., Aquestive Therapeutics Inc., Vedanta Biosciences Inc., Aimmune Therapeutics Inc., AnaptysBio Inc., Alladapt Immunotherapeutics Inc., Aravax Pty Ltd, Intrommune Therapeutics Inc., IgGenix Inc., DBV Technologies SA, Camallergy Ltd., HAL Allergy Group, Prota Therapeutics Pty Ltd.
Read the full peanut allergy treatment market report here:
https://www.thebusinessresearchcompany.com/report/peanut-allergy-treatment-global-market-report
What Are The Leading Geographic Regions In The Peanut Allergy Treatment Market?
North America was the largest region in the peanut allergy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peanut allergy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Peanut Allergy Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=15888&type=smp
Browse Through More Reports Similar to the Global Peanut Allergy Treatment Market 2026, By The Business Research Company
Peanut Allergy Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/peanut-allergy-treatment-global-market-report
Allergy Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/allergy-treatment-global-market-report
Food Allergy Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/food-allergy-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model